Table 3.
Incidence and severity of adverse events across CDK4/6 inhibitors.
| AEs | Any Grade No (%) |
Grade ≥ 3 No (%) |
Total Patients No 160 (%) |
|||||
|---|---|---|---|---|---|---|---|---|
| Abemaciclib No 49 |
Ribociclib No 53 |
Palbociclib No 58 |
Abemaciclib No 49 |
Ribociclib No 53 |
Palbociclib No 58 |
Any Grades | Grade ≥ 3 | |
| Anemia | ||||||||
| No | 44 (89.7) | 51 (96.2) | 51 (87.9) | 48 (97.9) | 53 (100) | 54 (93.1) | 146 (91.3) | 155 (96.8) |
| Yes | 5 (10.3) | 2 (3.8) | 7 (12.1) | 1 (2.1) | 0 (0) | 4 (6.9) | 14 (8.7) | 5 (3.2) |
| Neutropenia | ||||||||
| No | 38 (77.5) | 29 (54.7) | 24 (41.3) | 42 (85.7) | 43 (81.1) | 43 (74.1) | 92 (57.5) | 128 (80.0) |
| Yes | 10 (22.5) | 24 (45.3) | 34 (58.7) | 7 (14.3) | 10 (8.9) | 15 (25.9) | 68 (42.5) | 32 (20.0) |
| Thrombocytopenia | ||||||||
| No | 49 (100) | 53 (100) | 55 (94.8) | 49 (100) | 53 (100) | 56 (96) | 157 (98.1) | 158 (98.7) |
| Yes | 0 (0) | 0 (0) | 3 (5.2) | 0 (0) | 0 (0) | 2 (4) | 3 (1.9) | 2 (1.3) |
| Asthenia | ||||||||
| No | 37 (75.5) | 37 (69.8) | 48 (82.7) | 42 (85.7) | 49 (92.4) | 56 (96.5) | 122 (76.2) | 147 (91.9) |
| Yes | 12 (24.5) | 16 (30.2) | 10 (17.3) | 7 (14.3) | 4 (7.6) | 2 (3.5) | 38 (23.8) | 13 (8.1) |
| Diarrhea | ||||||||
| No | 24 (48.9) | 53 (100) | 58 (100) | 42 (85) | 53 (100) | 58 (100) | 135 (84.4) | 153 (95.7) |
| Yes | 25 (51.1) | 0 (0) | 0 (0) | 7 (5) | 0 (0) | 0 (0) | 25 (15.6) | 7 (4.3) |
| ALT/AST increased | ||||||||
| No | 49 (100) | 51 (96.2) | 55 (94.8) | 49 (100) | 52 (98) | 57 (98) | 155 (96.7) | 158 (98.7) |
| Yes | 0 (0) | 2 (3.8) | 3 (5.2) | 0 (0) | 1 (2) | 1 (2) | 5 (3.3) | 2 (1.3) |
| Qtc prolongation | ||||||||
| No | 49 (100) | 51 (96.2) | 58 (100) | 49 (100) | 51 (96.2) | 58 (100) | 158 (98.7) | 158 (98.7) |
| Yes | 0 (0) | 2 (3.8) | 0 (0) | 0 (0) | 2 (3.8) | 0 (0) | 2 (1.3) | 2 (1.3) |